Previous 10 | Next 10 |
BURNABY, British Columbia, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the Bank of America Securities...
Xenon Pharmaceuticals Inc. (XENE) Q3 2022 Results Conference Call November 08, 2022 4:30 PM ET Company Participants Sherry Aulin - Chief Financial Officer Ian Mortimer - President and Chief Executive Officer Chris Kenney - Chief Medical Officer Chris Von Segg...
Xenon Pharma press release ( NASDAQ: XENE ): Q3 GAAP EPS of -$0.57 misses by $0.05 . Revenue of $0.13M (-98.4% Y/Y) misses by $2.89M . Cash and cash equivalents and marketable securities were $752.2 million as of September 30, 2022, compared to $551.8 million a...
XEN1101 Phase 3 program launched with initiation of X-TOLE2 clinical trial Strong financial position of approximately $752 million to fully support XEN1101 Phase 3 program development and expected cash runway into 2026 Conference call at 4:30 pm ET today ...
BURNABY, British Columbia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the launch of its XEN1101 Phase 3 program with the initiation of the X-TOLE2 clinical trial, which will examine XEN1101 admin...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the Fed signaling oversized rate hikes for longer is the likely trajectory moving forward, it is understandable why investors are looking for stocks to sell rather than stocks to buy. Consumer spending continues to ris...
BURNABY, British Columbia, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2022 financial and operating results after the close of U.S. financial markets on Tuesday, N...
Raymond James has initiated Xenon Pharmaceuticals ( NASDAQ: XENE ) with an outperform rating citing the blockbuster potential of XEN1101, currently in phase 2 for epilepsy. The firm has a $52 price target (~46% upside based on Tuesday's close). Analyst Danielle Brill i...
Summary Today, we are revisiting Xenon Pharmaceuticals for the first time in 2022. The company is well-funded and advancing several compounds in its pipeline, one of which might have blockbuster potential. An investment analysis follows in the paragraphs below. "...
BURNABY, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in one-on-one investor meetings and a fireside chat presentation at the 17th Annual Wells F...
News, Short Squeeze, Breakout and More Instantly...
Xenon Pharmaceuticals Inc. Company Name:
XENE Stock Symbol:
NASDAQ Market:
Xenon Pharmaceuticals Inc. Website:
2024-06-25 17:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-15 18:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
VANCOUVER, British Columbia, June 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the Goldman Sachs 45th Annual Global Healthcare Conference taking place June 10-13, 2024 in M...